

Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

NCT06977126

Status	RECRUITING
Phase	Phase 1
Sponsor	University Health Network, Toronto
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (9)

- Female patients age e 18 years.
- Life expectancy of \>3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of d 2.
- Histologically confirmed metastatic advanced gynecological cancer. All epithelial subtypes are permitted. Patients receiving standard of care oncological treatment (i.e. chemotherapy and/or radiation) will be included.
- Patient is able to understand and is willing to sign a written informed consent document prior to registration/enrollment on to study.

... and 4 more (see full listing online)

Exclusion (15)

- Patient is a candidate for therapy with curative intent.
- Patient has a contraindication to PET/CT imaging, including, but not limited to, phobias associated with imaging (e.g. claustrophobia) and those who cannot lie still in the supine position for at least 20 minutes.
- Patients receiving nuclear medicine scans with other radiopharmaceutical agents (ex: 18F-FDG or other) during the study's exclusionary period will be excluded from the study.
- Patients with known myelodysplastic syndrome/acute myeloid leukemia.
- Treatment with an investigational drug within 15 days prior to study registration.

... and 10 more (see full listing online)

Locations (1 total)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada